Intuitive Surgical

Intuitive Surgical, Inc.

Company type	Public
Traded as	Template:NASDAQ Nasdaq-100 component S&P 100 component S&P 500 component
Industry	Medical Appliances & Equipment
Founded	1995 (1995)
Headquarters	Sunnyvale, California, U.S.
Key people	Gary S. Guthart (chairman) Dave Rosa (CEO) Craig Barratt (Board Member)
Products	da Vinci Surgical System
Revenue	Template:US$ (2024)
Operating income	Template:US$ (2024)
Net income	Template:US$ (2024)
Total assets	Template:US$ (2024)
Total equity	Template:US$ (2024)
Number of employees	15,638 (2024)
Website	intuitive.com

Intuitive Surgical, Inc. is a U.S.-based biotechnology firm that focuses on robotic surgical technologies, with its flagship product being the da Vinci Surgical System. It is publicly traded on the Nasdaq-100, S&P 100, and S&P 500 indexes. By the close of 2021, the company had installed 6,730 systems worldwide, holding a dominant position across markets in the United States, Europe, and Asia.

In 2024, Intuitive Surgical earned a spot on the Fortune 500 list at rank #497, underscoring its robust financial results and significant industry presence.

History

The origins of the da Vinci system trace back to research initiated in the late 1980s by Ajit Shah and Gary Guthart at SRI International, which received funding from the NIH and attracted DARPA's interest due to potential applications in remote battlefield surgeries.

In 1994, Dr. Frederic Moll recognized the system’s commercial promise but encountered initial reluctance from Guidant. The following year, Moll teamed up with John Freund, who obtained rights to SRI’s technology and co-founded Intuitive Surgical Devices, Inc., securing venture capital investments from firms such as Mayfield Fund and Morgan Stanley.

Initial prototypes carried names inspired by Leonardo da Vinci themes before the finalized product was branded as the da Vinci Surgical System. Marketing efforts commenced in Europe in 1999 while awaiting clearance from the FDA.

The company raised $46 million through its initial public offering in 2000. That same year, the FDA approved the system for general laparoscopic surgery, later extending approvals to include prostatectomy, thoracoscopy, cardiac surgery, and gynecologic operations.

Before going public, Intuitive Surgical was involved in patent disputes with competitor Computer Motion, creator of the ZEUS Robotic Surgical System. The two companies merged in 2003 under the Intuitive Surgical name, consolidating their market share and retiring the ZEUS platform.

Following this merger, Intuitive’s share price climbed sharply from about $14 to nearly $500 by 2015. This growth was fueled by a surge in system deployments—from just 60 units in 2002 to over 400 by 2014—and an increase in annual surgeries performed using their technology from fewer than 1,000 to more than half a million.

Finances

In the fiscal year 2017, Intuitive Surgical announced a net profit of US$660 million alongside revenues totaling US$3.129 billion, marking a 15.7% growth compared to the previous year. By November 2018, the company’s stock price surpassed $307 per share, with its market valuation climbing beyond US$58 billion.

Year	Revenue in mil. US$	Net income in mil. US$	Total assets in mil. US$	Price per share in US$	Employees	Stock split
2005	227	94	502	21.24
2006	373	72	672	35.65
2007	601	145	1,040	61.82
2008	875	204	1,475	85.48
2009	1,052	233	1,810	61.58
2010	1,413	382	2,390	104.33
2011	1,757	495	3,063	122.21
2012	2,179	657	4,059	172.93
2013	2,265	671	3,950	149.97	2,792
2014	2,132	419	3,959	147.55	2,978
2015	2,384	589	4,907	169.00	3,211
2016	2,704	736	6,487	212.10	3,755
2017	3,129	660	5,758	307.18	4,444	October 6, 2017: 3-for-1 stock split.
2018	3,724	1,125	7,847		5,527
2019	4,479	1,379	9,733		7,326
2020	4,360	1,600	11,000		8,000
2021	5,710	1,800	12,500		9,500	October 5, 2021: 3-for-1 stock split.
2022	6,220	2,000	14,000		11,000
2023	7,120	2,200	15,500		13,676
2024	8,350	2,600	17,000	521.96	15,000

da Vinci Surgical System

The da Vinci Surgical System represents a surgeon-operated robotic platform designed for minimally invasive operations via a console interface. Its primary application has been in prostatectomy procedures and is progressively being adopted for cardiac valve repairs and gynecological surgeries.

The initial versions were priced near $1.5 million while the da Vinci SI model introduced in 2009 carried a price tag close to $1.75 million. Alongside the upfront expense are ongoing maintenance fees and costs associated with surgical instruments. Although the substantial investment can pose challenges for hospitals to recoup costs initially, this system remains Intuitive Surgical’s cornerstone product that significantly contributes to its dominance and revenue expansion within the robotic surgery sector.

Lawsuits

In June 2018, Intuitive Surgical agreed to a $43 million settlement resolving shareholder class action lawsuits that originated in 2013. These legal actions accused the company of failing to adequately disclose injury risks linked to the da Vinci robot and thereby breaching federal securities regulations.

In 2021, Intuitive faced allegations of monopolistic practices concerning the aftermarket for surgical robot components. Rebotix Repair—a manufacturer specializing in replacement parts—filed claims accusing Intuitive of anti-competitive conduct and excessive pricing imposed on healthcare providers. Subsequently, Kaleida Health and Franciscan Health initiated comparable class action lawsuits. The dispute between Rebotix and Intuitive was settled privately in August 2022 just before trial commencement.

The case Sultzer v. Intuitive Surgical, Inc. involved assertions that a malfunction within the da Vinci robot led to a fatality caused by electrical arcing through the spinal column. Represented by Bradley Arant Boult Cummings law firm on behalf of Intuitive Surgical, the plaintiff withdrew the lawsuit on July 12, 2024.

External links

• FDA Records of Intuitive Surgical Product Recalls